By Sabela Ojea
Hims & Hers is expanding its weight-loss offering on its telehealth platform with the addition of Eli Lilly's Zepbound prescription and generic liraglutide.
The stock was up 7% to $31.62 in afternoon trading. Shares have risen around 31% year to date.
The telehealth-consultation platform on Tuesday said its aim is to bring customers more treatment options that best suit their needs.
"We've now expanded that choice even further by adding access to generic liraglutide and branded tirzepatide through our platform," the company said.
Hims & Hers' platform already offers weight-loss brands including Novo Nordisk's Ozempic and Wegovy.
Hims & Hers plans to continue expanding its weight loss offering to deliver a more personalized experience to its customer base, the company added.
"All of this is part of our long-term commitment to build the most comprehensive and personalized digital health platform for weight loss and beyond," Hims & Hers said.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
April 01, 2025 15:02 ET (19:02 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.